Bacil Pharma Ltd files SEBI Reg 29(1) disclosure for share acquisition by Niraj Rajnikant Shah

What Bacil Pharma Ltd announced

Bacil Pharma Ltd (BSE: 524516) filed a disclosure on 29 June 2026 under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The filing reports that Niraj Rajnikant Shah has acquired shares in the company that meet the threshold for a substantial acquisition. No additional details such as the number of shares, acquisition price, or percentage of total equity were provided in the filing.

Regulation 29(1) disclosure details

Regulation 29(1) obliges a listed company to inform the stock exchange when a person acquires shares that could give rise to a takeover obligation under the SAST framework. The purpose is to ensure transparency for all shareholders and to trigger any mandatory offer requirements if the acquirer crosses the prescribed shareholding limits. The filing simply records the occurrence of such an acquisition by Mr. Shah and confirms compliance with the regulatory requirement.

Key facts at a glance

Why this matters for investors

The disclosure signals that a party has reached a shareholding level that may trigger further regulatory scrutiny under the SAST regime. While the filing does not reveal the size of the stake, investors should monitor subsequent announcements for any offer to purchase remaining shares, changes in control, or board resolutions that may follow if the acquirer’s holding crosses the 25 % threshold. The filing itself does not imply any immediate dilution or change in corporate strategy.

Conclusion

Bacil Pharma Ltd has complied with SEBI’s requirement by reporting a substantial share acquisition by Niraj Rajnikant Shah on 29 June 2026. The filing contains no quantitative details, and no further corporate actions have been announced. Investors should await any future disclosures that may clarify the size of the stake and any related takeover implications.